Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03396874 · ClinicalTrials.gov registry record · Phase 2
Gallium-68 PSMA-11 PET in Patients With Biochemical Recurrence
A Phase 2 study, sponsored by University of Michigan.
- Completed
- Registry status
- Phase 2
- Development phase
- 1,435
- Enrollment target
NCT03396874 is a Phase 2 study that has completed, run by University of Michigan. The registered enrollment target is 1,435 participants.
The verdict
NCT03396874, a Phase 2 study, has completed, sponsored by University of Michigan.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 1,435 participants
- Enrollment target
Study Summary
This study evaluates the value of Gallium-68 labeled PSMA (68Ga-PSMA) for PET/CT imaging of prostate cancer recurrence. 68Ga-PSMA is a radioactive molecule, which binds to prostate cancer cells. Together with a PET/CT scanner, the distribution of 68Ga-PSMA can be determined in the body. To test this new drug, participants will receive an intravenous injection of Ga-68-PSMA and then have a PET/CT scan. The scan results will be made available to study participants and treating physicians.
Interventions
- DRUG 68Ga-PSMA
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,435 participants |
| Start Date | 2018-02-09 |
| Est. Completion | 2022-08-09 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03396874
The ClinicalTrials.gov registry entry for NCT03396874 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 1,435 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Michigan, which has 1,327 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which 68Ga-PSMA is the first listed.
NCT03396874 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03396874 about?
NCT03396874 is a clinical study titled "Gallium-68 PSMA-11 PET in Patients With Biochemical Recurrence". This study evaluates the value of Gallium-68 labeled PSMA (68Ga-PSMA) for PET/CT imaging of prostate cancer recurrence. 68Ga-PSMA is a radioactive molecule, which binds to prostate cancer cells. Together with a PET/CT scanner, the distribution of 68Ga-PSMA can be determined in the body. To test thi...
What is the current status of trial NCT03396874?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 1,435 participants. The study started on 2018-02-09. Estimated completion is 2022-08-09.
What interventions are being tested in trial NCT03396874?
The interventions under investigation include: 68Ga-PSMA (DRUG).
Who is sponsoring clinical trial NCT03396874?
This trial is sponsored by University of Michigan, which has 1,327 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.